Sulfur Containing Patents (Class 536/54)
  • Patent number: 9562065
    Abstract: The invention relates to a sucrose octasulfate of magnesium, having general formula I, the preparation method thereof and the use of same in the pharmaceutical and/or cosmetic field, wherein 0?n?4, n is an integer and Y represents OH, Cl, Br, I, NO3, C6H5O7, CH3CO2, CF3CO2 or —OCH3.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: February 7, 2017
    Assignee: PIERRE FABRE DERMO-COSMETIQUE
    Inventors: Séverine Jeulin, Hélène Hernandez-Pigeon, Luc Aguilar
  • Patent number: 9456860
    Abstract: Provided is a flowable bioresorbable tissue dressing comprising a gas-forming porogen and a gel or gel-forming solution. Also provided is kits for preparing the above-described tissue dressing. Further provided are methods of treating a tissue site of a mammal with the above dressing. Also provided is a reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: October 4, 2016
    Assignee: KCI Licensing, Inc.
    Inventor: Archel Ambrosio
  • Patent number: 9035042
    Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: May 19, 2015
    Assignee: ATTO-TEC GmbH
    Inventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
  • Patent number: 9024009
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: May 5, 2015
    Assignees: Janssen Pharmaceutica N.V., Mitsubishi Tanabe Pharma Corporation
    Inventors: Ahmed F. Abdel-Magid, Maureen Chislom, Steven Mehrman, Lorraine Scott, Kenneth M. Wells, Fan Zhang-Plasket, Sumihiro Nomura, Mitsuya Hongu, Yuichi Koga
  • Patent number: 9012412
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 21, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Bao-Ping Zhao
  • Publication number: 20150038694
    Abstract: A family of sugar-based molecules for therapeutic use, includes compounds with a structure having at least one sugar molecule with carrier function, bound to arsenic having active principle function, allowing the selective therapeutic treatment of tumoral pathologies and not, distinguished by a high cellular metabolism and, consequently, by a high glucose consumption. Based on the preferential glucose absorption according to the Warburg effect, the compounds are adapted to penetrate inside tumoral cells and not, distinguished by a high cellular metabolism, via the glucose molecule integrated in their structure, so as to determine the selective therapeutic treatment of the cells and, consequently, of the pathologies deriving therefrom, by the arsenic molecule chemically bound to above mentioned glucose molecule. Processes for the production of synthetic sugar-based compounds and extracted sugar-based compounds, produced from natural sources are also described.
    Type: Application
    Filed: February 19, 2013
    Publication date: February 5, 2015
    Applicant: XENUS SRL
    Inventors: Marco SALVETTI, Francesco NICOTRA, Giovanni RISTORI, Barbara LA FERLA, Giovanni CODACCI PISANELLI
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Patent number: 8933040
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: January 13, 2015
    Inventors: Craig A. Coburn, Kun Liu, Ernest J. McEacher, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou
  • Patent number: 8927507
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: January 6, 2015
    Inventors: Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Craig A. Coburn, Kun Liu, Harold G. Selnick
  • Publication number: 20150005485
    Abstract: Preparation and use of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides useful for the preparation of synthetic heparinoids.
    Type: Application
    Filed: January 29, 2014
    Publication date: January 1, 2015
    Applicant: ALCHEMIA LIMITED
    Inventors: Joachim SEIFERT, Latika SINGH, Tracie E. RAMSDALE, Michael L. WEST, Nicholas B. DRINNAN
  • Publication number: 20140377875
    Abstract: UV-Absorbing and fluorescent pl markers for isoelectric focusing separations and fluorescent labeling, and methods for making and using the markers.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 25, 2014
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Gyula Vigh, Ming-Chien Li
  • Patent number: 8901087
    Abstract: The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 2, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiang Chang, Kun Liu, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, Feng Shi, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Publication number: 20140350370
    Abstract: The disclosure provides a ligand that competes with glucose for binding the protein Concanavalin A (ConA) and competitive binding assays incorporating the ligand. The competing ligand binds to the primary and part or all of the extended binding sites of Concanavalin A. These and other aspects of the disclosure are useful for glucose monitoring (e.g., continuous glucose monitoring (CGM)).
    Type: Application
    Filed: April 8, 2014
    Publication date: November 27, 2014
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Brian M. Cummins, Gerard L. Coté
  • Publication number: 20140329267
    Abstract: It is provided a self-healing polymer network comprising transition metal thiolates, particularly thiolates of a transition metal that is able to self-assemble by metallophilic attractions, and more particularly Au(1), Ag(1), Cu(1) thiolates, or a mixture thereof, and, optionally, disulfide bonds, thiol and other thiolate groups. It is also provided several processes for the preparation of the self-healing polymer networks of the invention, as well as uses thereof.
    Type: Application
    Filed: November 27, 2012
    Publication date: November 6, 2014
    Inventors: Ibón Odriozola, Pablo Casuso, Natividad Díaz, Iraida Loinaz, Germán Cabañero, Hans-jürgen Grande
  • Publication number: 20140316129
    Abstract: A new method is described for the oversulfation of epiK5-N-sulfate to obtain an epiK5-amine-O-oversulfate with very high sulfation degree which, by subsequent N-sulfation, provides new epiK5-N,O-oversulfate-derivatives with a sulfation degree of at least 4, basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are new low molecular weight epiK5-N-sulfates useful as intermediates in the preparation of the corresponding LMW-epiK5-N,O-oversulfate-derivatives.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 23, 2014
    Inventors: Pasqua Anna ORESTE, Giorgio ZOPPETTI
  • Patent number: 8859757
    Abstract: A separating agent for optical isomers that uses a polysaccharide derivative provided by replacing all or a portion of the hydrogen atoms on the hydroxyl groups present in a polysaccharide with two specific atomic groups that act on optical isomers targeted for separation in an optical resolution, wherein the sum of the average introduction ratios of specific terminal substituents in these atomic groups is greater than 3.0 per monosaccharide unit.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: October 14, 2014
    Assignee: Daicel Corporation
    Inventor: Yuki Kawata
  • Publication number: 20140296506
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Application
    Filed: June 9, 2014
    Publication date: October 2, 2014
    Inventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
  • Publication number: 20140256657
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Bao-Ping Zhao
  • Publication number: 20140243283
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    Type: Application
    Filed: December 18, 2013
    Publication date: August 28, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Yeeman K. Ramtohul, Sanjoy Kumar Das, Caroline Cadilhac, Thumkunta Jagadeeswar Reddy, Louis Vaillancourt, Michel Gallant, Bingcan Liu, Evelyne Dietrich, Frederic Vallee, Julien Martel, Carl Poisson
  • Patent number: 8809300
    Abstract: Disclosed is a depolymerized glycosaminoglycan from Thelenota ananas (dTHG), weight average molecular weight of which is about 8000˜20000 Da, and monosaccharide components of which are acetylgalactosamine (GalNAc), glucuronic acid (GlcUA), fucose (Fuc) or their sulfates (expressed as —OSO3?), in which molar ratio of GalNAc:GlcUA:Fuc:—OSO3? is about 1:(1±0.3):(1±0.3):(3.5±0.5). Said dTHG is a potent endogenous inhibitor of factor X, which has good anticoagulant and antithrombotic activity, and can be used for the prevention and/or treatment of thrombotic diseases. Also provided is a method for preparing said dTHG, which comprises steps of 1) extracting and obtaining fucosylated glycosaminoglycan (THG) from the body wall of Thelenota ananas; 2) depolymerizing THG to obtain dTHG by method of peroxide depolymerization or method of peroxide depolymerization catalyzed by catalyst of the fourth period transition metal ions; 3) removing impurities with lower and/or higher molecular weight in dTHG.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: August 19, 2014
    Assignee: Shenzhen Neptunus Pharmaceutical Co., Ltd.
    Inventors: Jinhua Zhao, Hui Kang, Mingyi Wu, Weizhen Zeng, Zi Li, Yuan Gao, Jing Cui, Zhiguo Wang, Hanlin Feng, Lin Yu
  • Publication number: 20140220122
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: BHI Limited Partnership
    Inventors: Xianqi KONG, Mohamed ATFANI, Benoit BACHAND, Abderrahim BOUZIDE, Stephane CIBLAT, Sophie LEVESQUE, David MIGNEAULT, Isabelle VALADE, Xinfu WU, Daniel DELORME
  • Patent number: 8785416
    Abstract: The present invention relates to the use of a series of sulphated disaccharides for the preparation of a medicament for the treatment or prevention of a neurodegenerative and/or neurovascular disease, of a traumatic brain injury or of a traumatic spinal cord injury. The present invention also relates to the use of said sulphated disaccharides for the preparation of a neuroprotective medicament or of an antioxidant medicament. The neurodegenerative and/or neurovascular diseases are preferably: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: July 22, 2014
    Assignees: Bioiberica, S.A., Universidad Autonoma de Madrid
    Inventors: Josep Verges Milano, Antonio Garcia Garcia, Ramon Ruhi Roura, Eulalia Montell Bonaventura, Manuela Garcia Lopez, Carlos Raul Alaez Verson, Josep Escaich Ferrer, Javier Egea Maiquez, Pilar Negredo Madrigal, Silvia Lorrio Gonzalez
  • Publication number: 20140154717
    Abstract: The purpose of the present invention is to provide a method for highly accurately detecting a cancer cell. The method of the present invention is characterized by comprising imaging with the use of a fluorescently labeled L-glucose derivative. By using the method and imaging agent according to the present invention, a high contrast between a cancer cell and a normal cell can be obtained compared with the case that imaging is conducted with the use of a fluorescently labeled D-glucose derivative. According to this method, moreover, no fasting is needed for the determination. Thus, the imaging can be quickly carried out without imposing a burden on a patient.
    Type: Application
    Filed: March 29, 2012
    Publication date: June 5, 2014
    Applicants: HIROSAKI UNIVERSITY, PEPTIDE INSTITUTE, INC., RIKEN
    Inventors: Katsuya Yamada, Hirotaka Onoe, Tadashi Teshima, Toshihiro Yamamoto
  • Patent number: 8722633
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: May 13, 2014
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark Gary Bock
  • Publication number: 20140121179
    Abstract: The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 1, 2014
    Inventors: Neil Henderson, Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
  • Patent number: 8703720
    Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: April 22, 2014
    Assignee: Galecto Biotech AB
    Inventors: Hakon Leffler, Ulf J. Nilsson, Henrik Von Wachenfeldt
  • Patent number: 8697658
    Abstract: Compounds of formula (I): wherein X, Y, and Z are defined herein. Also disclosed are pharmaceutical compositions and therapeutical methods related to these compounds.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: April 15, 2014
    Assignee: National Health Research Institutes
    Inventors: Jinq-Chyi Lee, Yu-Sheng Chao
  • Publication number: 20140093907
    Abstract: Compounds and methods for determining transmembrane potential, monitoring changes in transmembrane potential, and/or drug screening are provided. In one aspect, compounds of the invention have a structure according to the formula: E-M-A, wherein A is a fluorophore, selected from xanthenes, eoumarins, cyanines, bimanes, and difluoroboradizaindacenes, charged at physiological pH; M is a molecular wire; and E is a hydrophobic moiety, wherein A and E are capable of being involved in a photo-induced, intramolecular electron transfer that quenches the fluorescence of A in response to a voltage condition. When in use, compounds of the invention are membrane-impermeant and oriented within the cell membrane such that the charged moiety localizes at the outer leaflet of the lipid bilayer and the hydrophobic moiety and molecular wire associate with the hydrophobic portion of the lipid bilayer.
    Type: Application
    Filed: May 21, 2012
    Publication date: April 3, 2014
    Applicant: The Regents of the University of California
    Inventors: Evan Walker Miller, Roger Y. Tsien
  • Publication number: 20140094600
    Abstract: A process for the preparation of compound of Formula (I) is provided.
    Type: Application
    Filed: March 12, 2012
    Publication date: April 3, 2014
    Applicant: WOCKHARD LIMITED
    Inventors: Kiran Kumar Gangakhedkar, Furqan Mohammed Diwan, Aniruddha Varangaonkar, Keshav Deo
  • Publication number: 20140031524
    Abstract: The quenching compounds of the invention are weakly luminescent cyanines that are substituted by one or more heteroaromatic quenching moieties. The quenching compounds of the invention exhibit little or no observable luminescence and efficiently quench a broad spectrum of luminescent compounds. The chemically reactive quenching compounds possess utility for labeling a wide variety of substances, including biomolecules. These labeled substances are highly useful for a variety of energy-transfer assays and applications.
    Type: Application
    Filed: April 17, 2013
    Publication date: January 30, 2014
    Applicant: AnaSpec Incorporated
    Inventor: AnaSpec Incorporated
  • Publication number: 20140031312
    Abstract: Disclosed are compositions and formulations comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and adapted for use in a bath or soak or bath beads, powders, salts, and oils, kits, and methods of treatment using the same. Also disclosed are lozenges, suppositories, patches, and topical creams comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and methods of treatment using the same. In some embodiments the joint conditions include osteoarthritis.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 30, 2014
    Applicant: Vital Medicine, LLC
    Inventors: Anjan Chatterji, Grant Cooper, David Schwartz
  • Publication number: 20140011765
    Abstract: Novel synthesis routes for preparation of thiodigalactosides and intermediates are presented. The method includes the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in situ, which in turn is directly reacted with a 3-azido-galactosyl bromide resulting in the 3,3?-di-azido-thio-di-galactoside before the thiol has a chance to reduce the azido 10 group. Hence, in situ formation of the 3-azido-galactosyl thiol from the thiouronium salt is essential in the synthesis procedure, because any other method that generate the thiol separately results in extensive unwanted azide reduction.
    Type: Application
    Filed: September 5, 2013
    Publication date: January 9, 2014
    Applicant: GALECTO BIOTECH AB
    Inventor: Ulf NILSSON
  • Patent number: 8614317
    Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: December 24, 2013
    Assignee: Atto-Tec GmbH
    Inventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
  • Publication number: 20130338099
    Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.
    Type: Application
    Filed: August 4, 2011
    Publication date: December 19, 2013
    Applicant: BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.
    Inventors: Xiaozheng Shu, Weiping Zhong, Yunyun Wang, Meixia Yu
  • Patent number: 8586550
    Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: November 19, 2013
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Jeongmin Kim, Suk Ho Lee, Junwon Lee, Kwang-Seop Song, Eun-Jung Park, Min Ju Kim, Hee Jeong Seo, Sung-Han Lee, Eun Jung Son, Jong Yup Kim, Suk Youn Kang, Younggyu Kong
  • Publication number: 20130261077
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    Type: Application
    Filed: March 6, 2013
    Publication date: October 3, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Youssef Laafiret Bennani, Caroline Cadilhac, Sanjoy Kumar Das, Evelyne Dietrich, Michel Gallant, Bingcan Liu, Oswy Z. Pereira, Yeeman K. Ramtohul, T. Jagadeeswar Reddy, Louis Vaillancourt, Constantin Yannopoulos, Frederic Vallee
  • Publication number: 20130225802
    Abstract: Disclosed is a process for the production of chondroitin sulphate, wherein N-acetyl-galactosamine residues sulphated at the 4- or 6-positions are present on the same polysaccharide chain.
    Type: Application
    Filed: November 11, 2011
    Publication date: August 29, 2013
    Applicant: ALTERGON S.A.
    Inventors: Emiliano Bedini, Mario De Rosa, Cristina De Castro, Annalida Di Nola, Michelangelo Parrilli, Odile Francesca Restaino, Chiara Schiraldi
  • Publication number: 20130197210
    Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. The invention also relates to a method of preparing a composition of the present disclosure. The invention further relates to a method of delivering a therapeutic agent, using the composition of the present disclosure, where a therapeutically effective amount of a therapeutic composition of the invention may be administered to a mammal (e.g. person or animal) in recognized need of the therapeutic.
    Type: Application
    Filed: August 15, 2012
    Publication date: August 1, 2013
    Applicants: CALANDO PHARMACEUTICALS, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie Bellocq, Jianjun Cheng
  • Patent number: 8492352
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: July 23, 2013
    Assignee: Sanofi
    Inventors: Joseph Schofield, Dave Smith, Patrick Soubayrol
  • Publication number: 20130174758
    Abstract: A binder comprising a polymeric binder comprising the products of a carbohydrate reactant and organic acid is disclosed. The binder is useful for consolidating loosely assembled matter, such as fibers. Fibrous products comprising fibers in contact with a carbohydrate reactant and an organic acid are also disclosed. The binder composition may be cured to yield a fibrous product comprising fibers bound by a cross-linked polymer. Further disclosed are methods for binding fibers with the carbohydrate based binder using an organic acid.
    Type: Application
    Filed: September 16, 2011
    Publication date: July 11, 2013
    Applicant: KNAUF INSULATION GMBH
    Inventor: Gert R. J. Mueller
  • Publication number: 20130142731
    Abstract: This invention relates generally to threads of hyaluronic acid, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, dermal fillers), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.
    Type: Application
    Filed: January 26, 2011
    Publication date: June 6, 2013
    Inventors: Geoffrey C. Gurtner, Jayakumar Rajadas, Kenneth N. Horne, Hiram Chee
  • Patent number: 8420790
    Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: April 16, 2013
    Assignee: Reliable Biopharmaceutical Corporation
    Inventors: Payal Parth Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
  • Publication number: 20130090298
    Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
    Type: Application
    Filed: June 10, 2011
    Publication date: April 11, 2013
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Jeongmin Kim, Suk Ho Lee, Junwon Lee, Kwang-Seop Song, Eun-Jung Park, Min Ju Kim, Hee Jeong Seo, Sung-Han Lee, Eun Jung Son, Jong Yup Kim, Suk Youn Kang, Younggyu Kong
  • Publication number: 20130078218
    Abstract: The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.
    Type: Application
    Filed: March 26, 2012
    Publication date: March 28, 2013
    Inventors: Yarlagadda S. Babu, Pooran Chand, Minwan Wu, Pravin L. Kotian, V. Satish Kumar, Tsu-Hsing Lin, Yahya El-Kattan, Ajit K. Ghosh
  • Publication number: 20130071443
    Abstract: Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Simon Cool, Victor Nurcombe
  • Publication number: 20130058957
    Abstract: An object of the present invention is to find a ligand for a DCIR and to search for an agonist and an antagonist for the DCIR. Specifically, disclosed are: a dendritic cell immunoreceptor agonist containing keratan sulfate-II (KS-II) as an active ingredient; an antibody against dendritic cell immunoreceptor, having a keratan sulfate-II-like dendritic cell immunoreceptor agonism; and an antibody against a dendritic cell immunoreceptor, having a keratan sulfate-II inhibitory dendritic cell immunoreceptor antagonism.
    Type: Application
    Filed: February 23, 2011
    Publication date: March 7, 2013
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Yoichiro Iwakura, Noriyuki Fujikado, Guangyu Ma
  • Publication number: 20130045946
    Abstract: The present invention describes sulodexide or at least one of its components for use in the reduction of circulating matrix metalloproteinase (MMPs), in particular MMP-9. Sulodexide and its composition are useful for the treatment of pathologies wherein the MMPs are involved, such as cardiovascular disease, cardiovascular disease caused by diabetes, varicose veins, chronic venous insufficiency (CVI), gastrointestinal ulcers, pulmonary disease, and neoplastic pathologies.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 21, 2013
    Inventors: Giuseppe Claudio Viscomi, Ferdinando Mannello, Cristiana Bruno
  • Publication number: 20130035481
    Abstract: The present invention relates to a method for preparation of the trisaccharide 6?-0-sialyllactose (formula (I)) or salts thereof as well as intermediates in the synthesis and for the use of 6?-0-sialyllactose salts in pharmaceutical or nutritional compositions.
    Type: Application
    Filed: February 21, 2011
    Publication date: February 7, 2013
    Applicant: GLYCOM A/S
    Inventors: Ignacio Pérez Figueroa, Ferenc Horváth, Gyula Dekany, Károly Ágoston, Ágnes Ágoston, István Bajza, Julien Boutet, Markus Hederos, Piroska Kovács-Pénzes, Lars Kröger, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas, Christian Risinger
  • Publication number: 20130017993
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 17, 2013
    Applicant: NOVARTIS AG
    Inventors: Gregory Raymond BEBERNITZ, Mark G. BOCK, Dumbala Srinivas REDDY, Atul Kashinath HAJARE, Vinod VYAVAHARE, Sandeep Bhausaheb BHOSALE, Suresh Eknath KURHADE, Videsh SALUNKHE, Nadim S. SHAIKH, Debnath BHUNIYA, P. Venkata PALLE, Lili FENG, Jessica LIANG
  • Publication number: 20130018181
    Abstract: The present invention provides a novel and highly stereoselective process for preparing gemcitabine, which is suitable for industrial production, wherein, it includes the following reactions. Additionally, the invention discloses the key intermediates. The definition for the groups of G1, G2, G3, G4, and G5 are described in the specification.
    Type: Application
    Filed: September 18, 2012
    Publication date: January 17, 2013
    Applicant: Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
    Inventors: Yongxiang XU, Hao YANG, Wen HOU